Compare Abeona Therapeutics Inc (ABEO) vs Ferrari NV (RACE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ferrari NV — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Ferrari NV trades at $374.88 (market cap $67.98B). The key difference: Ferrari NV is far larger — about 182.1× Abeona Therapeutics Inc's market cap, and Ferrari NV pays a 1.09% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | RACE | |
|---|---|---|
Market Cap | $373.32M | $67.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $517.65 |
52-Week Low | $4.17 | $314.63 |
Enterprise Value | $228.22M | $69.19B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Ferrari (RACE) trades at $386.99, up 0.52% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow. Recent news highlights the company's ongoing share buyback program and strategic moves like the new V12 model and EV developments. Analyst sentiment remains positive with a $467.50 consensus target.
The outlook is favorable given Ferrari's pricing power and hybrid sales growth, but risks include EV market reception and economic sensitivity. Wall Street's strong buy consensus (72% buy ratings) supports upside potential, though high valuation multiples warrant caution amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
